

Partnering within our communities to provide solutions for better health

P.O. Box 5119, Helena, MT 59604 Phone 406.443.6002 . Toll-Free 1.800.395.7961 Fax 406.513.1928 . Toll-Free 1.800.294.1350

Montana Medicaid Prior Authorization Request Form for Use of Orkambi® (lumacaftor/ivacaftor)

Member name:	Date:
Member ID:	DOB:
Prescriber name:	Specialty:
Prescriber phone:	Prescriber fax:
Please complete below information for applicable situ	ation, Initiation or Continuation of therapy:
 □ INITIATION OF THERAPY 1. Member is 1 year of age or older: □ Yes □ No 	
2. Laboratory results are attached confirming that mem cystic fibrosis transmembrane regulator (CFTR) gene	• •
3. Prescriber is a pulmonologist specializing in the treatment.	nent of cystic fibrosis: □ Yes □ No
4. Provider attests other current standard of care cystic f	ibrosis therapies have been optimized: ☐ Yes ☐ No
5. Provide baseline percent predicted expiratory volume	(ppFEV ₁): Date:
6. History of pulmonary exacerbations within the past 12	2 months is provided:
Initial authorization will be	issued for 6 months.
☐ CONTINUATION OF THERAPY	
1. Date medication started:	
2. Provider attests that member has been compliant on C medications: ☐ Yes ☐ No (Note: Verification of compliance is determined, the reauthorization provider to address member compliance.)	pliance will be made via Medicaid paid claims data.
3. Provider attests that in comparison to baseline, the me while on Orkambi therapy to one or more of the followa. Lung function improvement as demonstrated	
i. Provide current ppFEV ₁ :	_ Date:
b. Decline in pulmonary exacerbations: ☐ Yes [□ No

c. Stability or increase in body mass index (BMI): ☐ Yes ☐ No

4.	Prescriber is a pulmonologist specializing in the treatment of cystic fibrosis: ☐ Yes ☐ No
	Reauthorization will be issued for 6 months.

Please complete form, including required attachments and fax to Drug Prior Authorization Unit at 1-800-294-1350

11/2022